Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
ACTIVE_NOT_RECRUITING
Status
Conditions
- Allogeneic Hematopoietic Cell Transplantation (HCT)
- Advanced Hematologic Malignancies
- Acute Leukemia
- Chronic Myelogenous Leukemia
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
Interventions
- DRUG: Purified regulatory T-cells (Treg) plus CD34+ HSPC
- DRUG: Fludarabine
- DRUG: Melphalan
- DEVICE: CliniMACS CD34 Reagent System
- DRUG: Tacrolimus
- DRUG: Cyclophosphamide
- DRUG: Plerixafor
- DRUG: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent
- DRUG: Thiotepa
- DRUG: Mycophenolate Mofetil (MMF)
- DRUG: Ruxolitinib
- DRUG: Sirolimus
Sponsor
Stanford University
Collaborators